封面
市场调查报告书
商品编码
1085757

全球治疗进行性核上性麻痹的市场:按药物类型、按分销渠道、按地区规模、份额、前景、机会分析2022-2028

Progressive Supranuclear Palsy Treatment Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 195 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计进行性核上性麻痹治疗市场的增长将受到进行性核上性麻痹 (PSP) 发病率增加的推动。例如,根据美国国家神经疾病和中风研究所于 2020 年 7 月发表的一篇论文,全球 10 万人中约有 3 至 6 人患有进行性核上性麻痹,而在美国约有 2 万人患有这种疾病。核上性麻痹。

然而,进行性核上性麻痹的识别和诊断不足预计将阻碍市场增长。

本报告调查和分析全球进行性核上性麻痹治疗市场、市场推动者和限制因素、市场机会、COVID-19 的影响、按药物类型/分销渠道/地区进行的市场分析,我们提供竞争情况等。

目录

第 1 章调查目标/先决条件

第二章市场范围

  • 报告说明
    • 市场定义和范围
  • 执行摘要
    • 市场细分:按药物类型
    • 市场细分:按分销渠道
    • 市场细分:按地区
  • 连贯的机会图 (COM)

第三章市场动态/监管/趋势分析

  • 市场动态
    • 促进因素
    • 抑制器
    • 市场机会
  • 影响分析
  • 管道分析
  • 兑换场景
  • 流行病学
  • PEST 分析
  • 监管场景
  • 推出新产品
  • 联盟和协议
  • 市场趋势

第 4 章全球进行性核外麻痹治疗市场:COVID-19 流行病影响

  • COVID-19 市场情景
  • COVID-19 对进行性核上性麻痹治疗产品市场的影响

第 5 章全球渐进性核外皮炎治疗市场:按药物类型(2017-2028 年)

  • 简介
  • 多巴胺
  • 抗胆碱药
  • 三环类抗抑郁药
  • 其他

第 6 章全球渐进性核週性脊髓灰质炎治疗市场:按分销渠道(2017-2028 年)

  • 简介
  • 院内药房
  • 零售药店
  • 网上药店

第 7 章全球渐进性核外皮炎治疗市场:按地区(2017-2028 年)

  • 简介
  • 北美
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第8章竞争态势

  • 热图分析
  • 市场份额分析
    • AbbVie Inc.
    • Acorda Therapeutics Inc.
    • Biogen Inc.
    • Bristol-Myers Squibb Co.
    • Merck & Co. Inc.
    • UCB Biopharma
    • AlzProtect
    • Asceneuron Therapeutics
    • TauRx Pharmaceuticals
    • GlaxoSmithKline PLC
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
  • 分析师见解

第9章 章节

简介目录
Product Code: CMI4277

Progressive supranuclear palsy (PSP) is a neurodegenerative disease alike Parkinson's disease. The disease results from damage to nerve cells in the brain. One of the common symptomof the disease include inability to aim and move the eyes properly, where individuals may experience as blurring of vision. It is a rare brain disorder that affects body movement, control of walking i.e. gait and balance, speech, swallowing, vision, mood and behavior, and thinking.

Market Dynamics

Rising incidence of progressive supranuclear palsy (PSP) is expected to drive progressive supranuclear palsy treatment market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, reports that about 3-6 in every 100,000 people have progressive supranuclear palsy worldwide, and around 20,000 U.S. populace are suffering from progressive supranuclear palsy.

However, lack of identification or diagnosis of progressive supranuclear palsy are expected to hinder the market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, states that currently there are no specific laboratory tests or imaging approaches are definitively diagnose progressive supranuclear palsy.

Key features of the study:

  • This report provides in-depth analysis of the global progressive supranuclear palsy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global progressive supranuclear palsy treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global progressive supranuclear palsy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive supranuclear palsy treatment market.

Detailed Segmentation:

  • Global Progressive Supranuclear Palsy Treatment Market, By Drug Type:
    • Dopamine
    • Anticholinergic Agents
    • Tricyclic Antidepressants
    • Others
  • Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Progressive Supranuclear Palsy Treatment Market, By Region:
    • North America
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type:
      • Dopamine
      • Anticholinergic Agents
      • Tricyclic Antidepressants
      • Others
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • AbbVie Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Acorda Therapeutics Inc.
    • Biogen Inc.
    • Bristol-Myers Squibb Co.
    • Merck & Co. Inc.
    • UCB Biopharma
    • AlzProtect
    • Asceneuron Therapeutics
    • TauRx Pharmaceuticals
    • GlaxoSmithKline PLC
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Progressive Supranuclear Palsy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Market Scenario
  • Impact of COVID-19 Market on the Progressive Supranuclear Palsy Treatment Products

5. Global Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Dopamine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Anticholinergic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Tricyclic Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Progressive Supranuclear Palsy Treatment Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Acorda Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Biogen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol-Myers Squibb Co.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • UCB Biopharma
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AlzProtect
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Asceneuron Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • TauRx Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline PLC
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact